FindTrial
Sign In

Usage and safety of diethyl carbazine - a medicine to treat nasal allergy

Efficacy and safety of diethyl carbamazine in treatment of allergic rhinitis: a double blind randomised controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/03/024145
Enrollment
40
Registered
2020-03-20
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J309- Allergic rhinitis, unspecified

Interventions

Intervention1: Medical management: Diethyl carbamazine 100mg1 tablet morning and night for 21 days and montelukast and levocetirizine 1 tablet at night for 21 days Control Intervention1: Medical manag

Sponsors

Karpaga Vinayaga Institute of Medical sciences
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients with complaints suggestive of allergic rhinitis Patient not on any oral or nasal corticosteroids Patient willing to give consent

Exclusion criteria

Exclusion criteria: Other form of rhinitis Pregnancy Drug induced rhinitis Tumor of nose or sinus

Design outcomes

Primary

MeasureTime frame
Absolute eosinophil count Allergic symptoms Nasal eosinophilia Skin prick testTimepoint: 0,21 days—

Secondary

MeasureTime frame
Allergic symptomsTimepoint: 7,14 days—

Countries

India

Contacts

Public ContactDr S Mohana Karthikeyan

Karpaga Vinayaga Institute of Medical sciences and research centre

karthient@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 25, 2026